OrthoPediatrics Q3 2024 Earnings Report
Key Takeaways
OrthoPediatrics Corp. announced strong third-quarter results with a 37% increase in revenue compared to the same period last year. The company also increased its full-year revenue guidance for 2024, reflecting positive momentum and strategic execution across all business segments.
Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023
Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarter
Grew worldwide Trauma & Deformity revenue 31%, worldwide Scoliosis revenue 52%; Sports Medicine/Other revenue increased 50% in the third quarter of 2024 compared to the third quarter of 2023
Launched Enabling Technologies Division that will focus on new areas within digital health and advanced technology intended to differentiate the Company's core business, generate sustainable revenue, and access new markets and specialties beyond orthopedics
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Forward Guidance
The Company increased its revenue guidance from $200 million to $203 million to $202 million to $204 million, representing growth of 36% to 37% over 2023 revenue. The Company reiterated annual set deployment to be less than $20 million and reiterated $8 million to $9 million of Adjusted EBITDA for the full year of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income